Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Feb;26(2):109-11.

[Treatment of unresectable esophageal carcinoma by stenting with or without radiochemotherapy]

[Article in Chinese]
Jian-hua Fu  1 , Tie-hua Rong, Xiao-dong Li, Hui Yu, Guo-wei Ma, Hua-qing Min
Affiliations
  • PMID: 15059332
Clinical Trial

[Treatment of unresectable esophageal carcinoma by stenting with or without radiochemotherapy]

[Article in Chinese]
Jian-hua Fu et al. Zhonghua Zhong Liu Za Zhi. 2004 Feb.

Abstract

Objective: To evaluate the benefits of post-stenting radiotherapy and/or chemotherapy for unresectable esophageal carcinoma.

Methods: Fifty-three patients with unresectable esophageal carcinoma were randomly divided into two groups: patients in group A (n = 27) were treated with stenting alone, and those in group B (n = 26) were treated with stenting followed by radiotherapy and/or chemotherapy. Comparison was made by assessing their survival time, quality of life (QOL), degree of dysphagia, and stenting-related morbidity, respectively.

Results: There was no statistically significant improvement in dysphagia and QOL between the two groups. Although there was no difference in the frequency of stenting-related complications, re-stenosis occurred much less frequently in group B patients (P = 0.007). The mean survival time of patients was 245 +/- 41 days and 262 +/- 43 days in group A and group B, respectively. There was no significant difference between the two groups (P = 0.813).

Conclusion: Besides decreased recurrence of stenosis, post-stenting radiotherapy and/or chemotherapy does not provide additional benefits for survival.

PubMed Disclaimer